

In the claims:

Please replace the claims with the listing of claims below.

1. - 18. (cancelled)

19. (currently amended) A method for treating a subject afflicted with androgen-independent prostate cancer, wherein the prostate cancer is characterized by ~~prostate cancer cells which overexpress~~ overexpression of Her-2/neu protein, which method comprises administering to the subject (i) a therapeutically effective amount of a ~~humanized monoclonal antibody which selectively binds to an extracellular domain of the Her-2/neu protein~~ HERCEPTIN in conjunction with (ii) a therapeutically effective amount of an ~~antitumor chemotherapeutic agent paclitaxel~~, wherein treatment with the ~~monoclonal antibody~~ HERCEPTIN and the ~~chemotherapeutic agent paclitaxel~~ inhibits prostate cancer [[cell]] growth more than treatment with either the ~~monoclonal antibody~~ HERCEPTIN alone or the ~~chemotherapeutic agent paclitaxel~~ alone, so as to thereby treat the subject afflicted with androgen-independent prostate cancer.

20. - 30. (cancelled)